Page 161 - pharma 1 theoretical updated MNU_Neat

Clinical pharmacy 2024/2025 Level 3 Pharm D Pharmacology 1 (PO 502)
Drug used to reduce clotting (prevent thromboses)

prevent formation of clotting factors ➔ for ttt of thromboembolic
Anticoagulant
disease : prevent clot formation + avoid thrombosis
prevent aggregation of platelet (for prophylaxis of
Antiplatelet thromboembolic disease) : prevent clot formation + avoid

thrombosis
(for rapid dissolution of thromboemboli) : break down the
Fibrinolytic
existing clot

1- Thrombolytic Therapy

Thrombolytic drugs dissolve blood clots by activating Plasminogen (a group of

trypsin-like serine proteases (tPA) →Plasmin.
➢ Plasmin is a proteolytic enzyme capable of breaking cross-links between
MOA ➢ Because of these actions, thrombolytic drugs are also called: -
fibrin molecules which provide the structural integrity of blood clots

a. Plasminogen activators.

b. Fibrinolytic drugs.

First-Generation Second-Generation Third-Generation

Streptokinase Alteplase Reteplase
Urokinase Prourokinase Tenecteplase

(tissue plasminogen activator)
(Not Fibrin Specific) (Fibrin specific) Thrombolytic Agents

| P a g e 145